

Charles L Daley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8772279/publications.pdf>

Version: 2024-02-01

177
papers

16,923
citations

26630

56
h-index

15732

125
g-index

181
all docs

181
docs citations

181
times ranked

10483
citing authors

#	ARTICLE	IF	CITATIONS
1	American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 603-662.	5.6	1,828
2	The Epidemiology of Tuberculosis in San Francisco – A Population-Based Study Using Conventional and Molecular Methods. New England Journal of Medicine, 1994, 330, 1703-1709.	27.0	1,070
3	An Outbreak of Tuberculosis with Accelerated Progression among Persons Infected with the Human Immunodeficiency Virus. New England Journal of Medicine, 1992, 326, 231-235.	27.0	978
4	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 2016, 63, e147-e195.	5.8	916
5	The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. European Respiratory Journal, 2013, 42, 1604-1613.	6.7	683
6	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017, 64, e1-e33.	5.8	501
7	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017, 64, 111-115.	5.8	492
8	Clinical Significance of Differentiation of <i>Mycobacterium massiliense</i> from <i>Mycobacterium abscessus</i> . American Journal of Respiratory and Critical Care Medicine, 2011, 183, 405-410.	5.6	464
9	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, e1-e36.	5.8	367
10	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, 905-913.	5.8	357
11	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax, 2016, 71, i1-i22.	5.6	348
12	Epidemiology of human pulmonary infection with mycobacteria nontuberculous. Clinics in Chest Medicine, 2002, 23, 553-567.	2.1	344
13	Clinical and Microbiologic Outcomes in Patients Receiving Treatment for <i>Mycobacterium abscessus</i> Pulmonary Disease. Clinical Infectious Diseases, 2011, 52, 565-571.	5.8	343
14	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. European Respiratory Journal, 2020, 56, 2000535.	6.7	336
15	Adult Patients With Bronchiectasis. Chest, 2017, 151, 982-992.	0.8	282
16	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e93-e142.	5.6	282
17	Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 331-338.	5.6	277
18	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax, 2016, 71, 88-90.	5.6	274

#	ARTICLE	IF	CITATIONS
19	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 814-823.	5.6	212
20	Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2011, 11, 1.	2.9	204
21	Interferon- γ Release Assays and Tuberculin Skin Testing for Diagnosis of Latent Tuberculosis Infection in Healthcare Workers in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 77-87.	5.6	182
22	Macrolide Treatment for <i>Mycobacterium abscessus</i> and <i>Mycobacterium massiliense</i> Infection and Inducible Resistance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 917-925.	5.6	179
23	The Pharmacokinetics and Pharmacodynamics of Pulmonary <i>Mycobacterium avium</i> Complex Disease Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 559-565.	5.6	175
24	Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives. <i>Tuberculosis and Respiratory Diseases</i> , 2016, 79, 74.	1.8	172
25	Mycobacterial Characteristics and Treatment Outcomes in <i>Mycobacterium abscessus</i> Lung Disease. <i>Clinical Infectious Diseases</i> , 2017, 64, 309-316.	5.8	169
26	Factors Related to Response to Intermittent Treatment of <i>Mycobacterium avium</i> Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1283-1289.	5.6	162
27	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	6.7	159
28	Outcomes of <i>Mycobacterium avium</i> complex lung disease based on clinical phenotype. <i>European Respiratory Journal</i> , 2017, 50, 1602503.	6.7	154
29	Hypersensitivity Pneumonitis Reaction to <i>Mycobacterium avium</i> in Household Water. <i>Chest</i> , 2005, 127, 664-671.	0.8	151
30	<i>In Vitro</i> Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6324-6327.	3.2	146
31	<i>Mycobacterium abscessus</i> pulmonary disease: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2019, 54, 1801991.	6.7	140
32	Treatment Outcomes of Patients with HIV and Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1199-1206.	5.6	136
33	Intermittent Antibiotic Therapy for Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 96-103.	5.6	134
34	Pulmonary disease caused by rapidly growing mycobacteria. <i>Clinics in Chest Medicine</i> , 2002, 23, 623-632.	2.1	121
35	Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. <i>Chest</i> , 2017, 152, 800-809.	0.8	115
36	Effects of Gender and Age at Diagnosis on Disease Progression in Long-term Survivors of Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 614-626.	5.6	105

#	ARTICLE	IF	CITATIONS
37	Clinical Significance of a First Positive Nontuberculous Mycobacteria Culture in Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2014, 11, 36-44.	3.2	102
38	<i>Notes from the Field</i> : <i>Mycobacterium chimaera</i> Contamination of Heater-Cooler Devices Used in Cardiac Surgery—United States. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 1117-1118.	15.1	98
39	Early Therapy for Latent Tuberculosis Infection. <i>American Journal of Epidemiology</i> , 2001, 153, 381-385.	3.4	97
40	Effect of Drug Resistance on the Generation of Secondary Cases of Tuberculosis. <i>Journal of Infectious Diseases</i> , 2003, 188, 1878-1884.	4.0	93
41	Host and pathogen response to bacteriophage engineered against <i>Mycobacterium abscessus</i> lung infection. <i>Cell</i> , 2022, 185, 1860-1874.e12.	28.9	93
42	Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6758-6765.	3.2	90
43	Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. <i>European Respiratory Journal</i> , 2020, 55, 1900798.	6.7	89
44	<i>Mycobacterium avium</i> Complex Disease. <i>Microbiology Spectrum</i> , 2017, 5, .	3.0	87
45	Clofazimine-Containing Regimen for the Treatment of <i>Mycobacterium abscessus</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	86
46	Transcriptional Adaptation of Drug-tolerant <i>Mycobacterium tuberculosis</i> During Treatment of Human Tuberculosis. <i>Journal of Infectious Diseases</i> , 2015, 212, 990-998.	4.0	82
47	Treatment of <i>Mycobacterium avium</i> Complex Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 15.	1.8	80
48	A Molecular Epidemiological Assessment of Extrapulmonary Tuberculosis in San Francisco. <i>Clinical Infectious Diseases</i> , 2004, 38, 25-31.	5.8	72
49	Diagnosis and Treatment of Infections due to <i>Mycobacterium avium</i> Complex. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 569-576.	2.1	71
50	Treatment of <i>Mycobacterium abscessus</i> Pulmonary Disease. <i>Chest</i> , 2022, 161, 64-75.	0.8	69
51	Multiple Cytokines Are Released When Blood from Patients with Tuberculosis Is Stimulated with <i>Mycobacterium tuberculosis</i> Antigens. <i>PLoS ONE</i> , 2011, 6, e26545.	2.5	68
52	Drug susceptibility testing and pharmacokinetics question current treatment regimens in <i>Mycobacterium simiae</i> complex disease. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 173-176.	2.5	67
53	Nontuberculous Mycobacterial Infections in Cystic Fibrosis. <i>Clinics in Chest Medicine</i> , 2016, 37, 83-96.	2.1	65
54	You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for Tj ETQq0 0 0,rgBT /Overlock 10 T	0.9	64

#	ARTICLE	IF	CITATIONS
55	Genome Sequencing of <i>Mycobacterium abscessus</i> Isolates from Patients in the United States and Comparisons to Globally Diverse Clinical Strains. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3573-3582.	3.9	64
56	Potential Public Health Impact of New Tuberculosis Vaccines. <i>Emerging Infectious Diseases</i> , 2004, 10, 1529-1535.	4.3	62
57	The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. <i>European Respiratory Journal</i> , 2015, 45, 1177-1179.	6.7	62
58	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. <i>Annals of the American Thoracic Society</i> , 2016, 13, S379-S384.	3.2	58
59	Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. <i>Chest</i> , 2018, 154, 1311-1320.	0.8	57
60	Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifer Evaluation. <i>Journal of Clinical Microbiology</i> , 2016, 54, 274-282.	3.9	55
61	Nontuberculous Mycobacterial Infections in Cystic Fibrosis. <i>Thoracic Surgery Clinics</i> , 2019, 29, 95-108.	1.0	55
62	The Genome Sequence of <i>Mycobacterium massiliense</i> ™ Strain CIP 108297 Suggests the Independent Taxonomic Status of the <i>Mycobacterium abscessus</i> Complex at the Subspecies Level. <i>PLoS ONE</i> , 2013, 8, e81560.	2.5	54
63	Same meat, different gravy: ignore the new names of mycobacteria. <i>European Respiratory Journal</i> , 2019, 54, 1900795.	6.7	54
64	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 947-951.	5.6	53
65	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e178-e190.	9.1	51
66	Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of <i>Mycobacterium massiliense</i> Lung Disease. <i>Chest</i> , 2016, 150, 1211-1221.	0.8	48
67	Development of Macrolide Resistance and Reinfection in Refractory <i>Mycobacterium avium</i> Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1322-1330.	5.6	46
68	Improvement in Quality of Life after Therapy for <i>Mycobacterium abscessus</i> Group Lung Infection. A Prospective Cohort Study. <i>Annals of the American Thoracic Society</i> , 2016, 13, 40-48.	3.2	45
69	The Global Fight Against Tuberculosis. <i>Thoracic Surgery Clinics</i> , 2019, 29, 19-25.	1.0	45
70	<i>In Vitro</i> Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	44
71	Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant <i>Mycobacterium abscessus</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	44
72	Serodiagnosis of <i>Mycobacterium avium</i> complex pulmonary disease in the USA. <i>European Respiratory Journal</i> , 2013, 42, 454-460.	6.7	43

#	ARTICLE	IF	CITATIONS
73	Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6076-6083.	3.2	43
74	Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease. <i>Chest</i> , 2016, 150, 1222-1232.	0.8	42
75	Population Genomics of <i>Mycobacterium abscessus</i> from U.S. Cystic Fibrosis Care Centers. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1960-1969.	3.2	42
76	Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	41
77	Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 809-810.	5.6	40
78	Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. <i>Respiratory Medicine</i> , 2019, 151, 1-7.	2.9	38
79	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.8	36
80	The Prevalence and Significance of <i>Staphylococcus aureus</i> in Patients with Non-Cystic Fibrosis Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2018, 15, 365-370.	3.2	36
81	MULTIPLE DRUG-RESISTANT TUBERCULOSIS. <i>Infectious Disease Clinics of North America</i> , 1998, 12, 157-172.	5.1	35
82	Management of Multidrug Resistant Tuberculosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 044-059.	2.1	34
83	<i>Mycobacterium chimaera</i> Infections Related to the Heater-Cooler Unit Outbreak: A Guide to Diagnosis and Management. <i>Clinical Infectious Diseases</i> , 2019, 68, 1244-1250.	5.8	34
84	<i>Mycobacterium avium</i> Complex: Addressing Gaps in Diagnosis and Management. <i>Journal of Infectious Diseases</i> , 2020, 222, S199-S211.	4.0	34
85	Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?. <i>Infection, Genetics and Evolution</i> , 2012, 12, 832-837.	2.3	33
86	GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	33
87	Mortality Prediction in Pulmonary Mycobacterium Kansasi Infection and Human Immunodeficiency Virus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 793-798.	5.6	32
88	Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 619-624.	1.6	32
89	Management of Multidrug-Resistant Tuberculosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 310-324.	2.1	32
90	A Systematic Review of the Clinical Significance of Pulmonary Mycobacterium kansasii Isolates in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 883-889.	2.1	31

#	ARTICLE	IF	CITATIONS
91	Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. <i>European Respiratory Journal</i> , 2019, 54, 1801896.	6.7	31
92	Treatment outcomes of macrolide-susceptible <i>Mycobacterium abscessus</i> lung disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 293-295.	1.8	28
93	Detailed Analysis of the Radiographic Presentation of <i>Mycobacterium kansasii</i> Lung Disease in Patients With HIV Infection. <i>Chest</i> , 2008, 133, 875-880.	0.8	27
94	Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant <i>Mycobacterium massiliense</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
95	Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 414-421.	2.0	26
96	Genomic Analysis of Cardiac Surgery-Associated <i>Mycobacterium chimaera</i> Infections, United States. <i>Emerging Infectious Diseases</i> , 2019, 25, 559-563.	4.3	25
97	Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with <i>Mycobacterium avium</i> Complex and <i>Mycobacterium abscessus</i> Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	24
98	Molecular Epidemiology: A Tool for Understanding Control of Tuberculosis Transmission. <i>Clinics in Chest Medicine</i> , 2005, 26, 217-231.	2.1	22
99	Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. <i>PLoS ONE</i> , 2016, 11, e0155968.	2.5	22
100	The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 145-153.	0.7	21
101	Nontuberculous mycobacterial lung disease caused by <i>Mycobacterium avium</i> complex - disease burden, unmet needs, and advances in treatment developments. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1387-1401.	2.5	21
102	Efficacy and safety of tigecycline for <i>Mycobacterium abscessus</i> disease. <i>Respiratory Medicine</i> , 2019, 158, 89-91.	2.9	19
103	miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. <i>Scientific Reports</i> , 2020, 10, 3178.	3.3	19
104	Mutations in <i>gyrA</i> and <i>gyrB</i> in Moxifloxacin-Resistant <i>Mycobacterium avium</i> Complex and <i>Mycobacterium abscessus</i> Complex Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
105	Management of <i>Mycobacterium avium</i> complex and <i>Mycobacterium abscessus</i> pulmonary disease: therapeutic advances and emerging treatments. <i>European Respiratory Review</i> , 2022, 31, 210212.	7.1	18
106	IL-24 modulates IFN- γ expression in patients with tuberculosis. <i>Immunology Letters</i> , 2008, 117, 57-62.	2.5	17
107	Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4994-4996.	3.2	17
108	Nontuberculous Mycobacterial Musculoskeletal Infection Cases from a Tertiary Referral Center, Colorado, USA. <i>Emerging Infectious Diseases</i> , 2019, 25, 1075-1083.	4.3	17

#	ARTICLE	IF	CITATIONS
109	The Runny Nose. <i>Infectious Disease Clinics of North America</i> , 1988, 2, 131-148.	5.1	16
110	Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
111	“One-Two Punch” Synergistic β -Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. <i>Clinical Infectious Diseases</i> , 2021, 73, 1532-1536.	5.8	15
112	Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. <i>Respirology</i> , 2012, 17, 772-791.	2.3	14
113	Interferon-Gamma Release Assays. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 337-349.	1.4	14
114	Mycobacterial biomaterials and resources for researchers. <i>Pathogens and Disease</i> , 2018, 76, .	2.0	14
115	US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. <i>Chest</i> , 2018, 154, 1016-1023.	0.8	14
116	Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 851-861.	2.5	14
117	Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1033-1039.	3.2	14
118	Preventing Tuberculosis among HIV-Infected Persons: A Survey of Physicians' Knowledge and Practices. <i>Preventive Medicine</i> , 1999, 28, 437-444.	3.4	13
119	Treatment of Pulmonary Nontuberculous Mycobacterial Infections: Many Questions Remain. <i>Annals of the American Thoracic Society</i> , 2014, 11, 96-97.	3.2	13
120	Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. <i>Chest</i> , 2021, 160, 436-445.	0.8	13
121	Road ahead to respiratory health: Experts chart future research directions. <i>Respirology</i> , 2009, 14, 625-636.	2.3	12
122	Pandemic Influenza: Implications for Programs Controlling for HIV Infection, Tuberculosis, and Chronic Viral Hepatitis. <i>American Journal of Public Health</i> , 2009, 99, S333-S339.	2.7	12
123	Mycobacterium Avium Complex and Lung Cancer: Chicken or Egg? Both?. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1329-1330.	1.1	12
124	Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. <i>Respiratory Medicine</i> , 2019, 148, 37-42.	2.9	12
125	Nontuberculous mycobacteria in cystic fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 586-592.	2.6	12
126	Prevention of tuberculosis in HIV-infected patients. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 189-193.	3.1	12

#	ARTICLE	IF	CITATIONS
127	Tuberculosis Contact Investigations. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 779-781.	5.6	11
128	Update in Tuberculosis 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 550-555.	5.6	11
129	Species Distribution and Macrolide Susceptibility of <i>Mycobacterium fortuitum</i> Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
130	A Molecular-Beacon-Based Multiplex Real-Time PCR Assay To Distinguish <i>Mycobacterium abscessus</i> Subspecies and Determine Macrolide Susceptibility. Journal of Clinical Microbiology, 2021, 59, e0045521.	3.9	11
131	Genomic characterization of sporadic isolates of the dominant clone of <i>Mycobacterium abscessus</i> subspecies <i>massiliense</i> . Scientific Reports, 2021, 11, 15336.	3.3	11
132	<i>Mycobacterium tuberculosis</i> Infection among Asian Elephants in Captivity. Emerging Infectious Diseases, 2017, 23, 513-516.	4.3	10
133	Genetic mutations in linezolid-resistant <i>Mycobacterium avium</i> complex and <i>Mycobacterium abscessus</i> clinical isolates. Diagnostic Microbiology and Infectious Disease, 2019, 94, 38-40.	1.8	10
134	Mycobacterial Infections. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 001-002.	2.1	9
135	Editorial Commentary: Treatment for Multidrug-Resistant Tuberculosis: It's Worse Than We Thought!. Clinical Infectious Diseases, 2014, 59, 1064-1065.	5.8	9
136	Development of Drugs for Nontuberculous Mycobacterial Disease. Chest, 2021, 159, 537-543.	0.8	9
137	Transmission of Multidrug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 742-743.	5.6	8
138	Linezolid for multidrug-resistant tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 502-503.	9.1	8
139	Infections in "Noninfectious" Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S221-S226.	3.2	8
140	Non-tuberculous mycobacterial infections at San Francisco General Hospital. Clinical Respiratory Journal, 2015, 9, 436-442.	1.6	8
141	Mycobacterial Lung Disease Complicating HIV Infection. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 230-242.	2.1	8
142	Similar characteristics of nontuberculous mycobacterial pulmonary disease in men and women. European Respiratory Journal, 2019, 54, 1900252.	6.7	8
143	Tuberculosis Transmission Based on Molecular Epidemiologic Research. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 297-306.	2.1	7
144	Pulmonary Resection and Lung Transplantation for Bronchiectasis. Clinics in Chest Medicine, 2012, 33, 387-396.	2.1	6

#	ARTICLE	IF	CITATIONS
145	Mycobacterium chimaera Outbreak Response: Experience From Four United States Healthcare Systems. Open Forum Infectious Diseases, 2016, 3, .	0.9	6
146	ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1473-1475.	5.6	6
147	Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. European Respiratory Journal, 2019, 53, 1801636.	6.7	6
148	Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series. Journal of Infection, 2020, 80, 197-203.	3.3	6
149	Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 772-778.	0.7	6
150	Comparative safety of inhaled corticosteroids and macrolides in Medicare enrollees with bronchiectasis. ERJ Open Research, 2022, 8, 00786-2020.	2.6	6
151	Nontuberculous Mycobacteria. Clinics in Chest Medicine, 2015, 36, xi-xii.	2.1	5
152	Frequency of untreated hypogammaglobulinemia in bronchiectasis. Annals of Allergy, Asthma and Immunology, 2017, 119, 83-85.	1.0	4
153	A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy. Nature Clinical Practice Rheumatology, 2008, 4, 456-457.	3.2	3
154	Linezolid for multidrug-resistant tuberculosis – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 16-17.	9.1	3
155	Screening for Latent Tuberculosis Infection. JAMA Internal Medicine, 2016, 176, 1439.	5.1	3
156	Nontuberculous Mycobacterial Infections. , 2016, , 629-645.e6.		3
157	<i>Mycobacterium avium</i>Complex Disease. , 0, , 663-701.		3
158	Introducing the Nontuberculous Mycobacteria Series for CHEST. Chest, 2022, 161, 1-2.	0.8	3
159	Tuberculosis and Nontuberculous Mycobacterial Infections. , 2012, , 383-405.		2
160	Management of adverse drug events in TB therapy. , 2012, , 167-193.		2
161	Adjuvant therapy of bacterial meningitis. Pediatric Infectious Disease Journal, 1987, 6, 1160-1161.	2.0	1
162	The Molecular Epidemiology of Tuberculosis. , 2004, , 57-74.		1

#	ARTICLE	IF	CITATIONS
163	A Woman with a 15-Year History of Bronchiectasis and Recurrent Nontuberculous Mycobacterium Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2018, 15, 380-382.	3.2	1
164	Tuberculosis. <i>Clinics in Chest Medicine</i> , 2019, 40, xi.	2.1	1
165	Mycobacterium avium Complex Disease. <i>Respiratory Medicine</i> , 2019, , 301-323.	0.1	1
166	Nontuberculous Mycobacterial Infections. , 2009, , 879-895.		1
167	Nontuberculous Mycobacterial Infections. , 2010, , 793-810.		1
168	Adjuvant therapy of bacterial meningitis. <i>Pediatric Infectious Disease Journal</i> , 1987, 6, 1160-1161.	2.0	0
169	Reply to BÄrttger et al.. <i>Journal of Infectious Diseases</i> , 2005, 191, 824-824.	4.0	0
170	Other mycobacteria causing human disease. , 2009, , 60-74.		0
171	Serodiagnosis Of Mycobacterium Avium Complex Pulmonary Disease In The United States. , 2010, , .		0
172	Nontuberculosis Mycobacterial Disease. , 2019, , 498-506.e4.		0
173	Nontuberculous Mycobacterial Disease in Transplant Recipients. , 2019, , 503-517.		0
174	Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. <i>European Respiratory Journal</i> , 2019, 54, 1901806.	6.7	0
175	Serial sputum induction in nontuberculous mycobacterial pulmonary disease. <i>European Respiratory Journal</i> , 2020, 55, 1902196.	6.7	0
176	New Tuberculosis Vaccines May Have Serious Public Health Impact. <i>Emergency Medicine News</i> , 2004, 26, 67-68.	0.0	0
177	Tuberculosis and Nontuberculous Mycobacterial Infections. , 2008, , 385-408.		0